Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lu-PRRT Used More Intensively on Advanced Gastro-Entero-Pancreatic and Lung Neuroendocrine Neoplasms: Preliminary Results on Toxicity from a Randomized Study.
Grassi I, Nicolini S, Marini I, Matteucci F, Ranallo N, Di Iorio V, Sarnelli A, Foca F, Monti M, Fabbri L, Fantini L, Rossi A, Paganelli G, Severi S, Sansovini M. Grassi I, et al. Among authors: nicolini s. Neuroendocrinology. 2024 Nov 21:1-12. doi: 10.1159/000542328. Online ahead of print. Neuroendocrinology. 2024. PMID: 39571544 Free article.
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study.
Paganelli G, Sansovini M, Nicolini S, Grassi I, Ibrahim T, Amadori E, Di Iorio V, Monti M, Scarpi E, Bongiovanni A, Altini M, Urso L, Cittanti C, Matteucci F, Severi S. Paganelli G, et al. Among authors: nicolini s. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):152-160. doi: 10.1007/s00259-020-04873-0. Epub 2020 May 29. Eur J Nucl Med Mol Imaging. 2021. PMID: 32472437 Clinical Trial.
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.
Severi S, Grassi I, Bongiovanni A, Nicolini S, Marini I, Arpa D, Ranallo N, Azzali I, Di Iorio V, Sarnelli A, Manuela M, Amadori E, Fabbri L, Bartolini D, Tosatto L, Di Meco F, Gurrieri L, Riva N, Calabro L, Matteucci F, Paganelli G, Sansovini M. Severi S, et al. Among authors: nicolini s. J Nucl Med. 2024 Sep 3;65(9):1409-1415. doi: 10.2967/jnumed.123.266956. J Nucl Med. 2024. PMID: 39142827 Free PMC article.
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, Bongiovanni A, Antonuzzo L, Di Iorio V, Sarnelli A, Caroli P, Monti M, Scarpi E, Paganelli G. Ianniello A, et al. Among authors: nicolini s. Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1040-6. doi: 10.1007/s00259-015-3262-8. Epub 2015 Nov 27. Eur J Nucl Med Mol Imaging. 2016. PMID: 26611427 Clinical Trial.
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients.
Paganelli G, Sarnelli A, Severi S, Sansovini M, Belli ML, Monti M, Foca F, Celli M, Nicolini S, Tardelli E, Marini I, Matteucci F, Giganti M, Di Iorio V, De Giorgi U. Paganelli G, et al. Among authors: nicolini s. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3008-3017. doi: 10.1007/s00259-020-04856-1. Epub 2020 May 20. Eur J Nucl Med Mol Imaging. 2020. PMID: 32430583 Clinical Trial.
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, Monti M, Caroli P, Sarnelli A, Diano D, Di Iorio V, Grana CM, Cittanti C, Pieri F, Severi S, Paganelli G. Nicolini S, et al. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3260-3267. doi: 10.1007/s00259-021-05236-z. Epub 2021 Feb 18. Eur J Nucl Med Mol Imaging. 2021. PMID: 33604690 Free PMC article. Clinical Trial.
177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials.
Bongiovanni A, Nicolini S, Ibrahim T, Foca F, Sansovini M, Di Paolo A, Grassi I, Liverani C, Calabrese C, Ranallo N, Matteucci F, Paganelli G, Severi S. Bongiovanni A, et al. Among authors: nicolini s. Cancers (Basel). 2022 Dec 7;14(24):6022. doi: 10.3390/cancers14246022. Cancers (Basel). 2022. PMID: 36551507 Free PMC article.
44 results